MARKET

SYN

SYN

Synthetic
AMEX
1.070
+0.020
+1.90%
After Hours: 1.040 -0.03 -2.80% 19:53 09/28 EDT
OPEN
1.040
PREV CLOSE
1.050
HIGH
1.090
LOW
1.035
VOLUME
25.12K
TURNOVER
0
52 WEEK HIGH
4.900
52 WEEK LOW
1.030
MARKET CAP
16.95M
P/E (TTM)
-0.8433
1D
5D
1M
3M
1Y
5Y
Safety board recommends Synthetic Biologics proceed in cell transplant recipients trial
Synthetic Biologics (NYSE:SYN) on Tuesday said a data sa...
Seekingalpha · 1d ago
BRIEF-Synthetic Biologics Announces Positive Outcome Of DSMC Review In Clinical Trial Of Syn-004 In Allogeneic Hematopoietic Cell Transplant Recipients
BRIEF-Synthetic Biologics Announces Positive Outcome Of DSMC Review In Clinical Trial Of Syn-004 In Allogeneic Hematopoietic Cell Transplant Recipients
Reuters · 1d ago
Synthetic Biologics Announces Data And Safety Monitoring Committee (DSMC) Review In Phase 1b/2a Clinical Trial Of SYN-004 (ribaxamase) In Allogeneic Hematopoietic Cell Transplant Recipients
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2
Benzinga · 1d ago
Synthetic Biologics Gets Committee Nod to Progress SYN-004 Trial in Cell Transplant Recipients; Shares Rise
Synthetic Biologics Gets Committee Nod to Progress SYN-004 Trial in Cell Transplant Recipients; Shares Rise
MT Newswires · 1d ago
"Synthetic Biologics has received a Notice of Allowance for its US patent application 17/314,583 titled 'E. COLI-BASED PRODUCTION OF BETA-LACTAMASE (FOR MICROBIOME-PROTECTING THERAPY)'. Recent reverse split." - PatentGrants
https://twitter.com/PatentGrants/status/1569700636505296901   https://patentcenter.uspto.gov/#!/applications/17314583/ifw/docs
Benzinga · 09/13 14:54
Synthetic Biologics Announces Phase I Study To Evaluate The Safety, Tolerability, And Efficacy Of VCN-01 In Combination With Durvalumab In Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma Of The Head And Neck Was Presented At The ESMO Congress
Key data and conclusions featured in the Poster Presentation include:     · Safety: Treatment with VCN-01 had an acceptable safety profile when administered with durvalumab in the
Benzinga · 09/12 13:22
BRIEF-Synthetic Biologics Inc Files For Resale Of 2.46 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
BRIEF-Synthetic Biologics Inc Files For Resale Of 2.46 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Reuters · 09/06 21:23
Synthetic Biologics VCN-01 shows safety in phase 1 trial in head/neck cancer
Synthetic Biologics (NYSE:SYN) <a href="https://seekingalpha.c...
Seekingalpha · 09/06 09:47
More
About SYN
Synthetic Biologics, Inc. is a diversified clinical-stage company. The Company is focused on the development of oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient’s immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.